Could a drug calm this rare muscle and lung disease?

NCT ID NCT07377058

Recruiting now Disease control Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether tocilizumab, a drug that blocks inflammation, can improve symptoms and breathing in adults with anti-MDA5+ dermatomyositis, a rare autoimmune disease affecting muscles, skin, and lungs. About 110 participants will receive either tocilizumab or a placebo every two weeks for two months. Researchers will track symptom improvement and lung function changes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tocilizumab (a drug that blocks IL-6, given as an infusion every two weeks)
What this could lead to: If it works, this could point toward a new treatment option for anti-MDA5+ dermatomyositis, especially for lung problems.
What could go wrong: This is an early-phase trial with only 110 people, so results may not apply to everyone. The drug may not work better than placebo, and side effects like infections are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTI-MDA5 ANTIBODY-POSITIVE DERMATOMYOSITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anti-MDA5 dermatomyositis dermatomyositis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DERMATOMYOSITIS

Contacts and locations

Locations

Peking Union Medical College Hospital
RECRUITING

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.